KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 628 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
The role of preoperative immunonutrition on morbidity and immune response after cystectomy: protocol of a multicenter randomized controlled trial (INCyst Trial). PMID 39415282 · Trials · 2024-Oct-17 This is a protocol for an ongoing randomized trial in bladder cancer (oncology) using a drug-containing intervention (immunonutrition). It is not a completed trial report with results, and the specified time-to-event efficacy endpoints are not the primary focus. Therefore, it is ineligible for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Breast Cancer Index in Premenopausal Women With Early-Stage Hormone Receptor-Positive Breast Cancer. PMID 39145953 · JAMA Oncol · 2024-Oct-01 The record is a prospective-retrospective translational study (biomarker analysis) of the SOFT trial. While it involves a randomized trial with drug interventions and time-to-event endpoints, the trial phase (III/IIIb) is not explicitly confirmed in the provided text or metadata. The deterministic review signal indicates 'phase3_evidence_unclear'. Therefore, the criterion 'phase3_or_definitive' cannot be established, making eligibility uncertain. The report_type is 'other' as it is a translational/subgroup analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinical trial. PMID 39161079 · Cancer Commun (Lond) · 2024-Oct The record is an original report of a randomized Phase III trial with time-to-event endpoints in oncology. However, the abstract does not explicitly describe a drug-containing intervention. The intervention is described as 'concurrent chemoradiotherapy (CCRT)' but does not specify the chemotherapy drug(s) used. Without explicit evidence of a drug intervention, eligibility cannot be definitively established.
H L S B
旧组与严格 v3 交集 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Corrigendum to "Surrogate endpoints in phase III randomized trials of advanced gastroesophageal cancer: A systematic review and meta-analysis" [Crit. Rev. Oncol./Hematol. 201 (2024) 104416]. PMID 39127520 · Crit Rev Oncol Hematol · 2024-Oct The record is a published erratum to a systematic review and meta-analysis, not an original randomized trial report. It does not contain trial results, making it ineligible.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis. PMID 38760542 · Acta Pharmacol Sin · 2024-Oct This is a pooled pharmacometric analysis of Phase 2/3 trials for a drug (trilaciclib) in oncology (ES-SCLC). While it is human, randomized, and has Phase III components with a drug intervention, it does not report a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as required for eligibility. The analysis focuses on pharmacokinetics, exposure-response, and safety, not on a key efficacy endpoint like survival or progression-free survival.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Intensive treatment of triple negative breast cancer with residual positive axillary lymph node after neoadjuvant chemotherapy. PMID 39604957 · BMC Womens Health · 2024-Nov-27 Eligible for oncology, human, randomized, drug intervention, time-to-event endpoints, and original result. However, the required phase (III/IIIb or II/III) is not explicitly stated in the provided record, preventing confirmation of eligibility. Metadata indicates 'needs_review' with reason_code 'phase3_evidence_unclear'.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Randomized clinical trial on accelerated preoperative hyperfractionated radiotherapy versus preoperative hyperfractionated radio-chemotherapy in locally advanced rectal cancer. PMID 39240387 · Br J Radiol · 2024-Nov-01 Eligibility requires explicit confirmation of Phase III/IIIb or Phase II/III; this is not established in the provided record.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. PMID 39385035 · Nature · 2024-Nov The abstract describes a biomarker-focused mechanistic analysis derived from the POSEIDON trial, but does not explicitly report any primary or secondary time-to-event efficacy endpoint (OS, PFS, etc.), Kaplan-Meier survival curves, or hazard ratios. It is not the formal primary or secondary result report of the trial.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Inadequate staging and excessive surveillance imaging: Evaluating the magnitude of benefit of targeted therapies in lung cancer. PMID 39368224 · Eur J Cancer · 2024-Nov The record is a journal article reviewing methodological aspects of several phase III trials. It does not present original, formal results of a single randomized trial. While it references oncology, human, randomized, phase III trials with drug interventions, it lacks a primary or secondary time-to-event efficacy endpoint result. Therefore, it is excluded as a non-eligible review.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Oral decitabine/cedazuridine versus intravenous decitabine for acute myeloid leukaemia: A randomised, crossover, registration, pharmacokinetics study. PMID 39313917 · Br J Haematol · 2024-Nov The record describes a randomized, crossover, registration, pharmacokinetics study in acute myeloid leukemia. It includes a primary time-to-event efficacy endpoint (OS) and a drug-containing intervention (decitabine/cedazuridine). However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types). The deterministic review signal 'phase3_evidence_unclear' is confirmed; the phase cannot be established from the given information. Therefore, it does not meet the required 'phase3_or_definitive' criterion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine. PMID 39265780 · Contemp Clin Trials · 2024-Nov The study is a randomized trial of opioid agonist therapy integration in primary care, not an oncology trial. While it involves humans and a drug intervention, it lacks a primary time-to-event efficacy endpoint (e.g., OS, PFS) and is not a Phase II/III or Phase III cancer trial. The primary outcome is a composite quality health indicator score, not a time-to-event measure.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
[Pembrolizumab and radiochemotherapy in locally advanced cervical cancer-the prospective, randomised KEYNOTE-A18 phase 3 study]. PMID 39230593 · Strahlenther Onkol · 2024-Nov Cannot confirm eligibility due to missing abstract and explicit time-to-event endpoint signal. Title indicates phase 3 randomized trial in oncology with pembrolizumab, but no efficacy endpoint is mentioned.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3. PMID 39178526 · Gynecol Oncol · 2024-Nov The study is a secondary analysis of recurrence patterns from the JGOG 3017 trial, which is a randomized oncology trial with drug intervention and time-to-event endpoints. However, the provided metadata and abstract do not explicitly confirm the trial phase as Phase III/IIIb or Phase II/III, which is a required criterion for eligibility. Therefore, it is excluded due to insufficient phase evidence.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Treatment-Switching Adjustment of Overall Survival in CheckMate 227 Part 1 Evaluating First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Nonsmall Cell Lung Cancer. PMID 39097467 · Clin Lung Cancer · 2024-Nov The abstract describes a primary analysis (overall survival) from the CheckMate 227 Phase III trial. However, the specific report presented is a 'treatment-switching adjustment' analysis, a statistical re-analysis to correct for crossover bias, not the primary trial report. The criteria require the original formal-result report. Since the deterministic review flagged phase as unclear and the publication metadata does not explicitly confirm 'Phase III' in the provided fields, phase eligibility cannot be definitively established. The report type is 'secondary' as it is a methodological adjustment of the primary result.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial. PMID 38809003 · Cancer Biol Med · 2024-May-29 The record describes a randomized, double-blind, drug-intervention trial in oncology with a primary time-to-event endpoint (PFS). However, the trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the title, abstract, or metadata. The deterministic review also flagged phase evidence as unclear. Therefore, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer. PMID 37889120 · Clin Cancer Res · 2024-May-15 The record describes a secondary biomarker analysis of two randomized trials, including MONARCH 3 (a Phase III trial). However, the abstract does not explicitly confirm the trial phase, and the report's primary focus is on genomic mechanisms, not the definitive presentation of the trial's primary efficacy endpoint. Therefore, eligibility is uncertain pending confirmation of the trial phase and whether this is considered a primary or secondary result report.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Common variation in a long non-coding RNA gene modulates variation of circulating TGF-β2 levels in metastatic colorectal cancer patients (Alliance). PMID 38745123 · BMC Genomics · 2024-May-14 The study is eligible for oncology, human, randomized, phase III, and drug intervention criteria. However, it is excluded because it does not have a time-to-event efficacy endpoint; it is a biomarker/genetic study (pQTL analysis) from a trial cohort, not a report of the trial's efficacy results.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
An Immersive Virtual Reality Intervention for Preoperative Anxiety and Distress Among Adults Undergoing Oncological Surgery: Protocol for a 3-Phase Development and Feasibility Trial. PMID 38743939 · JMIR Res Protoc · 2024-May-14 The record is a protocol for a multi-phase feasibility study, not a report of a completed Phase III/IIIb or Phase II/III randomized trial with a drug-containing intervention and a primary time-to-event efficacy endpoint. The intervention is virtual reality, not a drug. No results for OS, PFS, DFS, or other time-to-event outcomes are presented.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Horwitz SM, Scarisbrick JJ, Dummer R, et al. Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data. Blood Adv. 2021;5(23):5098-5106. PMID 38743412 · Blood Adv · 2024-May-14 Eligibility is indeterminate because the presence of a primary/key secondary time-to-event efficacy endpoint cannot be confirmed from the available metadata. The study meets criteria for oncology, randomized, Phase III, drug intervention, and original result, but the critical 'time_to_event' criterion is not established.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling. PMID 38680089 · Cancer Med · 2024-May The record describes a randomized trial of clofarabine in ALL. While it is oncology, human, randomized, drug-interventional, and reports original results, two key criteria are not met: 1) The trial phase is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata (deterministic review flagged 'phase3_evidence_unclear'). 2) The primary analysis presented is a multi-state model investigating intermediate events (going off-protocol, MRD negativity) and their transitions, not a standard primary time-to-event efficacy endpoint like OS, PFS, or EFS for the overall trial population. The abstract mentions EFS was the endpoint in the original report ('No improvement of event-free survival (EFS) was observed'), but this specific analysis deepens that with multi-state modeling, which is a secondary/exploratory analysis, not the primary Kaplan-Meier or HR result for the trial's main endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Brief Report of Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non-Small-Cell Lung Cancer: Outcomes by Tumor PD-L1 Expression in the Phase 3 POSEIDON Study. PMID 38584069 · Clin Lung Cancer · 2024-May The record is a Phase 3 drug intervention trial in oncology. However, the title indicates it is a 'Brief Report' focusing on outcomes by PD-L1 expression subgroup, which is a post-hoc or secondary analysis, not a primary efficacy report of the randomized trial. Furthermore, there is no explicit signal in the title, abstract (missing), or metadata for a primary time-to-event efficacy endpoint, Kaplan-Meier plot, or hazard ratio, which are required for eligibility.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Fluoropyrimidine type, patient age, tumour sidedness and mutation status as determinants of benefit in patients with metastatic colorectal cancer treated with EGFR monoclonal antibodies: individual patient data pooled analysis of randomised trials from the ARCAD database. PMID 38402342 · Br J Cancer · 2024-May The record describes a pooled analysis of individual patient data from multiple randomized trials, not an original formal-result report of a single Phase III/IIIb or Phase II/III trial. While it meets criteria for oncology, human, randomized, time-to-event, and drug intervention, it fails the 'original_result' criterion. The phase of the included trials is not explicitly confirmed as Phase III/IIIb or Phase II/III in the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison. PMID 38383713 · Bone Marrow Transplant · 2024-May The record describes an original, randomized, comparative study (MC-FludT.14/L Trial II) with primary time-to-event efficacy endpoints (OS, NRM, relapse incidence) for drug-containing conditioning regimens in oncology. However, the explicit clinical trial phase (Phase III/IIIb or Phase II/III) is not confirmed in the provided metadata (e.g., title, abstract, publication types), which is required for eligibility under the specified criteria.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702]. PMID 38195363 · Ann Oncol · 2024-May The record is a corrigendum to a published erratum for a Phase III randomized trial of atezolizumab in NSCLC. However, the abstract is empty, and the metadata does not confirm the presence of a time-to-event efficacy endpoint (OS, PFS, etc.) or a Kaplan-Meier plot/Hazard Ratio. Therefore, eligibility cannot be determined.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical efficacy analysis of surgical treatment for spinal metastasis under the multidisciplinary team using the NOMS decision system combined with the revised Tokuhashi scoring system: a randomized controlled study. PMID 38515197 · J Orthop Surg Res · 2024-Mar-21 The study is an oncology randomized trial with original results but does not meet the core eligibility criteria: it lacks a drug-containing intervention and a primary time-to-event efficacy endpoint. It focuses on surgical decision-making and clinical outcomes like complications and quality of life.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Clinical characteristics and MRI based radiomics nomograms can predict iPFS and short-term efficacy of third-generation EGFR-TKI in EGFR-mutated lung adenocarcinoma with brain metastases. PMID 38515096 · BMC Cancer · 2024-Mar-21 The study is an oncology analysis on human patients with a time-to-event endpoint and a drug intervention, but it is not a Phase III/IIIb or Phase II/III randomized trial report. It is a retrospective predictive modeling study using data from a cohort, not a formal report of a randomized trial's primary or secondary efficacy results. The phase is not established in the metadata, and the design is not a prospective randomized trial comparing drug interventions.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study. PMID 38096462 · J Clin Oncol · 2024-Mar-10 Eligibility is indeterminate because the required Phase III/IIIb or Phase II/III evidence is not explicitly established in the provided record. All other criteria are met.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial. PMID 38127335 · JAMA Oncol · 2024-Mar-01 The record meets all criteria except explicit confirmation of the trial phase. The abstract does not state Phase III, IIIb, or II/III. Publication types do not include phase information. Without explicit phase metadata, eligibility cannot be confirmed, but all other required criteria are satisfied.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Nomogram for predicting pathological response to neoadjuvant treatment in patients with locally advanced gastric cancer: Data from a phase III clinical trial. PMID 38523553 · Cancer Med · 2024-Mar The study is a secondary analysis (nomogram development) from a Phase III trial, with pathological response as the primary endpoint, not the primary time-to-event efficacy endpoint required for inclusion.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A hypoxia biomarker does not predict benefit from giving chemotherapy with radiotherapy in the BC2001 randomised controlled trial. PMID 38387404 · EBioMedicine · 2024-Mar The report is an original, randomized, oncology trial with a drug intervention and time-to-event endpoints, but it is a post-hoc biomarker subgroup analysis, not the primary efficacy report. Additionally, the trial phase is not explicitly confirmed in the provided metadata. Therefore, it does not meet the inclusion criteria for a primary formal-result report of a Phase III/IIIb or Phase II/III trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. PMID 38177857 · Nat Med · 2024-Mar While the title references a primary result from a definitive Phase 3 RCT, the provided record is only the Author Correction (an erratum). The abstract is empty, so the core time-to-event endpoint signal cannot be verified. The metadata indicates it is not the original primary formal report. Therefore, eligibility cannot be established.
H
仅历史库存 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Corrigendum to "Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score" [Eur. Urol. 83(5) (2024) 432-440]. PMID 38176992 · Eur Urol · 2024-Mar Record is a published erratum, not an original result report. While it references a randomized oncology trial with a time-to-event endpoint, the provided metadata does not explicitly confirm a drug intervention or definitive Phase III/IIIb status, and the report type is an erratum, not a primary result.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Patient-reported frailty phenotype (PRFP) vs. International Myeloma Working Group frailty index (IMWG FI) proxy: A comparison between two approaches to measuring frailty. PMID 38104480 · J Geriatr Oncol · 2024-Mar The record is a secondary analysis comparing frailty assessment methods using pooled data from Phase 3 trials. It does not report time-to-event efficacy outcomes for a drug intervention, is not an original trial report, and does not meet the criteria for inclusion as a definitive randomized controlled trial result.
H S B
严格 v3 独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Autologous cell immunotherapy (IGV-001) with IGF-1R antisense oligonucleotide in newly diagnosed glioblastoma patients. PMID 38060340 · Future Oncol · 2024-Mar The record is a published protocol (Phase IIb) for an ongoing trial. It does not report final or interim efficacy results, and the Phase IIb designation does not meet the Phase III/IIIb or Phase II/III definitive trial requirement. Therefore, it is excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial. PMID 38016651 · Br J Haematol · 2024-Mar The record describes a randomized, oncology, human trial with a drug intervention and a time-to-event endpoint (OS). However, the trial phase is not explicitly established in the provided metadata or abstract, preventing confirmation of Phase III/IIIb or Phase II/III eligibility. Therefore, eligibility cannot be determined with the required certainty.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial. PMID 38906541 · BMJ · 2024-Jun-21 Cannot confirm a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, HR) from the provided metadata (abstract is empty, no publication_types for results, no keywords/MESH indicating endpoints). The title suggests a clinical trial report, but without explicit endpoint information, eligibility is indeterminate.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Outcomes of subsequent antilymphoma therapies after second-line axicabtagene ciloleucel or standard of care in ZUMA-7. PMID 38315832 · Blood Adv · 2024-Jun-11 The report is a subgroup analysis of subsequent treatments after second-line therapy in a randomized trial, not the primary analysis of the trial's main comparison. Furthermore, the trial phase (Phase III/IIIb or II/III) is not explicitly established in the provided metadata, which is a required criterion. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Additional copies of 1q negatively impact the outcome of multiple myeloma patients and induce transcriptomic deregulation in malignant plasma cells. PMID 38849344 · Blood Cancer J · 2024-Jun-07 The study is a pre-specified or post-hoc biomarker analysis from a randomized trial, not the primary or definitive report of the trial's overall results. The trial phase is not established in the metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Two by Two Factorial Design using Metformin and Curcumin for Second Primary Head and Neck Cancer Prevention Trial. PMID 38918654 · Asian Pac J Cancer Prev · 2024-Jun-01 The record is a clinical trial protocol for a Phase IIB/III randomized trial with drug intervention. While it meets oncology, human, randomized, phase, and drug criteria, it is a protocol without results and the primary endpoint is the incidence of second primary tumors, not a time-to-event endpoint like OS, PFS, DFS, etc. Therefore, it is excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. PMID 38763153 · Lancet · 2024-Jun-01 The record describes a randomized trial with a drug intervention (androgen deprivation therapy) and a primary time-to-event efficacy endpoint (metastasis-free survival) in prostate cancer, a human malignant neoplasm. It reports original results with hazard ratio and survival percentages. However, the explicit trial phase (e.g., Phase III) is not provided in the title, abstract, or publication metadata. Without confirmation of Phase III/IIIb or Phase II/III status, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Morbidity After Mechanical Bowel Preparation and Oral Antibiotics Prior to Rectal Resection: The MOBILE2 Randomized Clinical Trial. PMID 38506889 · JAMA Surg · 2024-Jun-01 Study is an oncology-related randomized trial but lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.). The intervention is bowel preparation (mechanical and oral antibiotics) for surgical complication reduction, not a drug-containing cancer therapy. The primary endpoint is the Comprehensive Complication Index (morbidity), not a Kaplan-Meier or time-to-event efficacy outcome.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Efficacy and safety of paclitaxel liposome versus paclitaxel in combination with carboplatin in the first-line chemotherapy for ovarian cancer: a multicenter, open-label, non-inferiority, randomized controlled trial. PMID 39282588 · J Natl Cancer Cent · 2024-Jun The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title/abstract). While it is a randomized, controlled, definitive trial in oncology with a time-to-event endpoint and a drug intervention, the eligibility criterion requiring explicit confirmation of Phase III/IIIb or Phase II/III cannot be met from the given information.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Exploring management and outcomes of elderly patients with glioblastoma using data from two randomised trials (GEINO1401/EX-TEM). PMID 38630385 · J Neurooncol · 2024-Jun The record describes a combined secondary analysis of two randomized trials (GEINO1401/EX-TEM) exploring outcomes by age. While it reports time-to-event endpoints (PFS, OS) and includes drug interventions, it is not a primary result report of a single Phase III/IIIb or Phase II/III trial. The trial phase of the underlying studies is not explicitly stated in the provided metadata.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer. PMID 39080281 · NPJ Breast Cancer · 2024-Jul-30 The trial is an oncology randomized study in humans with a drug intervention and reports time-to-event (OS) outcomes. However, the trial phase is not explicitly stated in the provided information as Phase III/IIIb or Phase II/III, which is a strict requirement for eligibility. Additionally, the abstract identifies OS as a secondary endpoint, which may not satisfy the 'primary/key secondary' criterion if OS was not designated as such for this specific publication.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Dual-wavelength dye laser combined with betamethasone injection for treatment of keloids: protocol of a randomised controlled trial. PMID 38986560 · BMJ Open · 2024-Jul-09 The record describes a protocol for a randomized controlled trial evaluating a laser + steroid injection for keloids (benign fibroproliferative tumours). It is not an oncology (malignant neoplasm) study, does not report time-to-event outcomes (OS, PFS, etc.), and is a protocol without results.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an international randomized controlled trial according to the Trials within Cohorts design. PMID 38970096 · Trials · 2024-Jul-05 This is a protocol for an ongoing trial, not a report of original results. The metadata does not establish the trial phase, drug intervention, or a time-to-event endpoint. It is excluded as a protocol-without-results.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Comparison between Reirradiation by Stereotactic Body Radiation Therapy and Moderately Hypofractionated Radiotherapy in Combination with Temozolomide for Treatment of Recurrent High Grade Glioma. PMID 39068585 · Asian Pac J Cancer Prev · 2024-Jul-01 The study is a randomized, human oncology trial with a drug intervention (temozolomide) and time-to-event endpoints (PFS, OS). However, the abstract and metadata do not explicitly state the trial phase. The deterministic review indicates 'phase3_evidence_unclear' and the publication types include 'Randomized Controlled Trial' but not a specific Phase III designation. Without explicit phase information from the record, the 'phase3_or_definitive' criterion cannot be met, rendering the study ineligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study. PMID 38426292 · Haematologica · 2024-Jul-01 The study is a Phase III randomized trial in oncology with a drug intervention, but the primary focus and reported endpoint is health-related quality of life, not a formal time-to-event efficacy analysis (e.g., OS, PFS). Therefore, it is excluded as per criteria requiring a primary/key secondary time-to-event endpoint.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Survival of patients with ruptured gastrointestinal stromal tumour treated with adjuvant imatinib in a randomised trial. PMID 38862742 · Br J Cancer · 2024-Jul The record describes a secondary analysis of a randomized Phase III trial (SSG XVIII/AIO) evaluating adjuvant imatinib in high-risk GIST, with a focus on the subset of patients with rupture. It reports recurrence-free survival and overall survival (time-to-event endpoints) and includes a drug intervention. The publication is classified as a 'secondary' report type because it is a pre-specified or post-hoc analysis of the primary trial, but it is an original result report with formal efficacy endpoints, not a post-hoc subgroup, biomarker-only, quality-of-life, safety-only, or health-economic analysis.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study. PMID 38830959 · Leukemia · 2024-Jul The record meets oncology, human, phase III, time-to-event, and drug intervention criteria, but it fails to explicitly establish randomization, which is a required criterion for eligibility. Therefore, it is excluded.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -